
Lupin receives U.S. FDA approval for Tolvaptan tablets with 180-day exclusivity
Lupin Limited shares are in focus today following the announcement that the company has received U.S. FDA approval for its generic version of Tolvaptan Tablets, used for treating autosomal dominant polycystic kidney disease (ADPKD). This approval positions Lupin as the exclusive first-to-file generic manufacturer, granting the company 180 days of marketing exclusivity in the United States. Tolvaptan targets high-value U.S. nephrology market
Lupin's Tolvaptan Tablets – in strengths of 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg – are bioequivalent to Jynarque®, a brand marketed by Otsuka Pharmaceutical Company Ltd. The drug is indicated to slow kidney function decline in adults at risk of rapidly progressing ADPKD.
According to IQVIA data, Jynarque® generated estimated annual U.S. sales of $1.47 billion for the fiscal year ended December 2024, highlighting the significance of this launch for Lupin's U.S. business.
The drug will be manufactured at Lupin's Nagpur facility in India, and the company confirmed that a market launch is imminent. Strategic remarks from Lupin leadership
Vinita Gupta, CEO of Lupin, stated:
'We are very pleased to have obtained approval for generic Tolvaptan from the U.S. FDA. This marks a significant entry into the nephrology segment and demonstrates our commitment to addressing the unmet needs of patients globally.' Why this matters First-to-file status secures Lupin a 6-month window without generic competition in the U.S.
Entry into the nephrology segment marks a new therapy area for expansion.
Reinforces Lupin's U.S. presence, already a stronghold for the company's revenues. About Lupin
Lupin Limited, headquartered in Mumbai, is a global pharma leader with a footprint in over 100 markets. The company operates 15 manufacturing sites and 7 research centers worldwide. It has a strong presence in multiple therapeutic areas, including respiratory, cardiovascular, anti-diabetic, and CNS segments. Its subsidiaries also cover diagnostics, digital health, and complex generics.
For more details, visit: www.lupin.com FAQs
What is Tolvaptan used for?
It is prescribed to slow kidney function decline in adults with ADPKD.
What is Lupin's advantage with this approval?
Lupin is the first generic filer, granting it 180-day market exclusivity in the U.S.
How big is the market opportunity?
The reference drug Jynarque® saw U.S. sales of approximately $1.47 billion in 2024.
When will Lupin launch the product?
Lupin has confirmed the launch is planned soon, with manufacturing handled at its Nagpur plant.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Applied Medical Technology, Inc. Unveils Redesigned Mobile App Aligned with Recent Website Refresh
BRECKSVILLE, Ohio., June 10, 2025 /PRNewswire/ -- Applied Medical Technology, Inc. (AMT), a leader in innovative medical devices, is proud to announce the launch of its redesigned mobile application, AMT ONE Source®. This strategic update follows a successful website redesign completed late 2024, ensuring that both platforms now offer a cohesive, user-friendly digital experience. Enhancing User Experience Across PlatformsThe redesigned mobile app mirrors the modern, intuitive design language introduced during the website refresh. With a renewed focus on user experience and engagement, the mobile platform now features streamlined interfaces and updated information. "In today's fast-paced healthcare environment, it is essential that our digital platforms are not only reliable but also easy to navigate and visually appealing," said Bill Bentley, National Sales Manager. "Created with our youngest patients in mind, the redesign was thoughtfully developed to be more engaging, age-appropriate, and easy to navigate—helping children and their families feel more supported and empowered throughout their healthcare journey." Key Features and Benefits Unified Design Aesthetic: The mobile app adopts the clean, modern design previously launched on the website, providing a consistent look and feel across all digital touchpoints. Richer Content Experience: The app now features an expanded content database, providing a broader range of resources and information to support users with timely, relevant, and easy-to-access content. Improved Performance: The redesigned app features enhanced performance, with a new backend architecture that allows for faster content updates, easier maintenance, and more frequent improvements to keep the experience fresh and relevant. AMT partnered with Cleveland-Ohio based software company, Stream 9, on the redesign. Their strong track record in software design and development brought deep technical expertise and a strategic approach. "We're fortunate in our business to develop custom software projects for businesses of all kinds; but it's especially rewarding to work on a project that will deliver such a direct benefit to patients and their caregivers. AMT brought a clear vision to the table, and we worked closely together to translate that into a modern, scalable, and user-friendly digital experience," shared Kirk Miesle, Founder of Stream 9. The AMT ONE Source® app is available now on the App Store and Google Play. About AMT: Applied Medical Technology, Inc. (AMT) is a global leader in enteral and surgical devices committed to improving lives through innovation. For 40 years, AMT has bridged the gap between medical technology and patient needs, collaborating with healthcare professionals and users to develop high-quality, life-enhancing solutions. Our holistic approach prioritizes the well-being of the whole person, not just the device they use. View original content to download multimedia: SOURCE Applied Medical Technology, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
Nick Wodeshick from The Alternatives Channel Announces Publication Titled - CPSL: The ETF Seeking 100% Downside Protection in All Seasons
New York, New York--(Newsfile Corp. - June 10, 2025) - Nick Wodeshick is excited to announce the publication of this recent article "CPSL: The ETF Seeking 100% Downside Protection in All Seasons" on the VettaFi Alternatives Channel. This article explores how the Calamos Laddered S&P 500® Structured Alt Protection ETF (CPSL) may offer investors the potential for both upside participation and 100% downside protection in an uncertain market environment. CPSL: The ETF Seeking 100% Downside Protection in All Seasons With the market outlook uncertain, financial advisors may want to build a portfolio strategy prepared for both good and bad news. This is where the Calamos suite of Structured Protection ETFs® could come into play. Given the shifting market conditions, the Calamos Laddered S&P 500® Structured Alt Protection ETF (CPSL) offers an interesting use case. A fund of funds, CPSL equally allocates across 12 monthly Calamos S&P 500® Structured Alt Protection ETFs®, whose outcome periods are staggered across different months. These underlying ETFs blend capped equity upside with downside risk mitigation. After paying fees and expenses, these funds protect against 100% of losses incurred over their respective outcome periods. Read the full article here: About Calamos Investments As a proven provider of alternative ETF strategies, Calamos Investments offers a wide selection of ETFs listed in the U.S. In total, these funds represent over $800 million in assets under management, according to FactSet data. About VettaFi VettaFi is a leading provider of data-driven insights and specialized services for asset managers and investors, bringing together a wealth of expertise to support client success. At the core of VettaFi is a commitment to fostering strong relationships and delivering innovative solutions that help clients engage, grow, and thrive in an increasingly complex financial landscape. For more information about VettaFi, please visit Media Contact: help@ To view the source version of this press release, please visit
Yahoo
44 minutes ago
- Yahoo
Nick Wodeshick from The Alternatives Channel Announces Publication Titled - CPSL: The ETF Seeking 100% Downside Protection in All Seasons
New York, New York--(Newsfile Corp. - June 10, 2025) - Nick Wodeshick is excited to announce the publication of this recent article "CPSL: The ETF Seeking 100% Downside Protection in All Seasons" on the VettaFi Alternatives Channel. This article explores how the Calamos Laddered S&P 500® Structured Alt Protection ETF (CPSL) may offer investors the potential for both upside participation and 100% downside protection in an uncertain market environment. CPSL: The ETF Seeking 100% Downside Protection in All Seasons With the market outlook uncertain, financial advisors may want to build a portfolio strategy prepared for both good and bad news. This is where the Calamos suite of Structured Protection ETFs® could come into play. Given the shifting market conditions, the Calamos Laddered S&P 500® Structured Alt Protection ETF (CPSL) offers an interesting use case. A fund of funds, CPSL equally allocates across 12 monthly Calamos S&P 500® Structured Alt Protection ETFs®, whose outcome periods are staggered across different months. These underlying ETFs blend capped equity upside with downside risk mitigation. After paying fees and expenses, these funds protect against 100% of losses incurred over their respective outcome periods. Read the full article here: About Calamos Investments As a proven provider of alternative ETF strategies, Calamos Investments offers a wide selection of ETFs listed in the U.S. In total, these funds represent over $800 million in assets under management, according to FactSet data. About VettaFi VettaFi is a leading provider of data-driven insights and specialized services for asset managers and investors, bringing together a wealth of expertise to support client success. At the core of VettaFi is a commitment to fostering strong relationships and delivering innovative solutions that help clients engage, grow, and thrive in an increasingly complex financial landscape. For more information about VettaFi, please visit Media Contact: help@ To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data